Join to access to all OVN content. Join for Free
Why and How MSLs Can Adapt the Mindset of a Lifelong Learner
lifelong learning for MSLs personal accountability in learning engaging with KOLs platforms for MSL learning social media for professional growth

Why and How MSLs Can Adapt the Mindset of a Lifelong Learner


Share This Article


Summary

In this episode, Sarah Snyder shares her insights on lifelong learning for MSLs, emphasizing the importance of personal accountability and balancing different learning types. She discusses strategies for managing decision fatigue and setting achievable learning goals, providing valuable resources and book recommendations. Sarah encourages starting before feeling fully ready and highlights the significance of performance tracking. The conversation delves into engaging with KOLs and the potential of platforms like Clubhouse and TikTok for MSLs. Sarah concludes with advice on using social media strategically for professional growth, urging listeners to take action in their learning journey.

Sarah Snyder, Associate Director, Medical Affairs at Biosplice Therapeutics discusses why it is so important for MSLs to be lifelong learners.

Sarah shares…

πŸ‘‰ How to apply your learning style for success

πŸ‘‰ Resources and platforms that may be effective for MSL learning

πŸ‘‰ Why personal development can be as important as scientific learnings

πŸ‘‰ Her personal recommendations on recent books, podcasts, etc.

πŸ‘‰ How to tie personal development to performance

Click for Source
lifelong learning for MSLs, personal accountability in learning, engaging with KOLs, platforms for MSL learning, social media for professional growth

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Explore OVN